Project: A first-in-class therapy to cure ALS through antigen-specific restoration of immune tolerance

Acronym	ALPHAVAC (Reference Number: 115368)
Duration	01/09/2021 - 01/09/2024
Project Topic	We will develop a tolerance induction therapy to treat amyotrophic lateral sclerosis (ALS). To identify and validate a therapy target, we will construct recombinant RNA replicons and immunise mice with candidate primary self-antigens (pSAgs) of ALS to induce ALS symptoms. Next, we will deploy Amarna’s SVec vector platform to develop a therapy that restores immune tolerance to the pSAg and stops the autoimmune reaction, thus curing ALS. This project will deliver efficacy data for the ALS therapy.
Network	Eurostars 2
Call	Eurostars Cut–off 15

Project partner

Number	Name	Role	Country
1	Amarna Therapeutics	Coordinator	Netherlands
2	Redoxis AB	Partner	Sweden